Saturday, October 3, 2026

Nikkei 225 Over 3% Down In The Last 5 Sessions

Nikkei 225 Over 3% Down In The Last 5 Sessions

(VIANEWS) - Nikkei 225 (N225) has been up by 3.31% for the last 5 sessions. At 21:08 EST on Thursday, 4 April, Nikkei 225 (N225) is $39,033.64.

About Nikkei 225's yearly highs and lows, it's 42.31% up from its 52-week low and 5% down from its 52-week high.

Volatility

Nikkei 225's last week, last month's, and last quarter's current intraday variation average was a negative 0.38%, a negative 0.04%, and a positive 0.81%, respectively.

Nikkei 225's highest amplitude of average volatility was 0.83% (last week), 0.83% (last month), and 0.81% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Nikkei 225's is considered to be oversold (<=20).

News about

  • According to Zacks on Wednesday, 3 April, "Currently, pre-market futures are slightly down: the Dow -42 points, the S&P 500 -11 (off all-time highs notched just last week) and the Nasdaq -63 points. "
  • According to Zacks on Wednesday, 3 April, "Clean Harbors (CLH Quick QuoteCLH - Free Report) stock has gained 43.4%, outperforming 29.5% and 28.3% growth of the industry it belongs to and the Zacks S&P 500 Composite in the past year, respectively."
  • According to FXStreet on Wednesday, 3 April, "The momentum from a strong fourth quarter continued into 2024 as the S&P 500 notched the best first quarter since 2019, returning 10.1% through March 28 (U.S. markets were closed on March 29 for Good Friday).", "The top stock on the Nasdaq and the second-best performer on the S&P 500 last quarter was semiconductor juggernaut NVIDIA (NASDAQ: NVDA). "

More news about Nikkei 225 (N225).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com